Alector (ALEC) investor relations material

Executive summary

• Focused on developing therapies for neurodegenerative diseases, leveraging the proprietary ABC platform for blood-brain barrier delivery and advancing preclinical programs in Alzheimer's and Parkinson's disease.

• Recent pipeline setbacks include discontinuation of key clinical trials for latozinemab and nivisnebart after failing to meet endpoints, including the global Phase 2 PROGRESS-AD trial for nivisnebart.

• Maintains a robust pipeline with multiple ABC-enabled candidates in preclinical and IND-enabling stages, including AL037/AL137, AL050, and AL164.

• Workforce reductions of 13% in March 2025 and 47% in October 2025 to align resources with strategic priorities and reduce costs.

Financial highlights

• Collaboration revenue was $1.0 million for Q1 2026, down from $3.7 million in Q1 2025, due to lower manufacturing activity for discontinued trials.

• Net loss for Q1 2026 was $22.9 million ($0.21/share), improved from $40.5 million ($0.41/share) in Q1 2025, reflecting lower R&D and G&A expenses after restructuring.

• Cash, cash equivalents, and marketable securities totaled $206.5 million as of March 31, 2026.

• R&D expenses decreased to $17.8 million in Q1 2026 from $33.6 million in Q1 2025.

• G&A expenses decreased to $8.1 million in Q1 2026 from $14.7 million in Q1 2025.

Outlook and guidance

• Cash runway expected to fund operations at least through 2027, supported by cost reductions and existing capital.

• Focus shifting to advancing preclinical and research pipeline, with decreased expenses for discontinued clinical programs.

• Targeting IND submission for AL037/AL137 in Q1 2027 and advancing AL050 and AL164 through preclinical and IND-enabling studies.

• Additional capital will be required for future development and commercialization; potential sources include equity, debt, and collaborations.